Heron Therapeutics, Inc. (NASDAQ:HRTX) Holdings Raised by Palisade Capital Management LP

Palisade Capital Management LP boosted its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 34.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 5,286,931 shares of the biotechnology company's stock after purchasing an additional 1,360,542 shares during the period. Palisade Capital Management LP owned approximately 3.47% of Heron Therapeutics worth $11,631,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of HRTX. Nicolet Advisory Services LLC purchased a new position in Heron Therapeutics during the 4th quarter worth $25,000. RFP Financial Group LLC purchased a new stake in shares of Heron Therapeutics in the first quarter valued at about $26,000. Argent Advisors Inc. purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at about $31,000. Focus Partners Wealth purchased a new stake in shares of Heron Therapeutics in the fourth quarter valued at about $31,000. Finally, State of Wyoming boosted its holdings in shares of Heron Therapeutics by 573.5% in the fourth quarter. State of Wyoming now owns 29,736 shares of the biotechnology company's stock valued at $45,000 after acquiring an additional 25,321 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Stock Up 0.7%

Shares of NASDAQ:HRTX traded up $0.02 during trading on Friday, reaching $2.17. The stock had a trading volume of 823,589 shares, compared to its average volume of 2,184,221. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.73. The business has a fifty day moving average price of $2.06 and a 200-day moving average price of $1.96. The stock has a market cap of $330.29 million, a P/E ratio of -36.08 and a beta of 1.18.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. As a group, equities analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on HRTX. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, April 11th. HC Wainwright initiated coverage on shares of Heron Therapeutics in a report on Monday, June 9th. They set a "buy" rating and a $6.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Friday, June 6th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.